Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-8448b6f56d-xtgtn Total loading time: 0 Render date: 2024-04-24T20:50:30.757Z Has data issue: false hasContentIssue false

11 - Therapeutic decision making in SCT for amyloidosis

Published online by Cambridge University Press:  05 August 2013

By
Reinhold Munker ,
Hillard M. Lazarus  and
Kerry Atkinson
Edited by
Reinhold Munker ,
Gerhard C. Hildebrandt ,
Hillard M. Lazarus  and
Kerry Atkinson
Reinhold Munker
Affiliation:
Louisiana State University, Shreveport
Gerhard C. Hildebrandt
Affiliation:
University of Utah
Hillard M. Lazarus
Affiliation:
Ireland Cancer Center, Case Western Reserve University Hospital, Cleveland
Kerry Atkinson
Affiliation:
University of Queensland
Get access

Summary

A summary is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Chapter
Information
The BMT Data Book
Including Cellular Therapy
 , pp. 133 - 138
Publisher: Cambridge University Press
Print publication year: 2013

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Bahlis, NJ & Lazarus, HM. 2006. Multiple myeloma-associated AL amyloidosis: is a distinctive therapeutic approach warranted?Bone Marrow Transplant 38: 7–15.CrossRefGoogle ScholarPubMed
Chow, LQM, Bahlis, N, Russell, J, et al. 2005. Autologous transplantation for primary systemic AL amyloidosis is feasible outside a major amyloidosis referral center. Bone Marrow Transplant 36: 591–596.CrossRefGoogle Scholar
Cibeira, MT, Sanchorawala, V, Seldin, DC, et al. 2011. Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 412 patients. Blood 118: 4346–4352.CrossRefGoogle Scholar
Comenzo, RL & Gertz, MA. 2002. Autologous stem cell transplantation for primary systemic amyloidosis. Blood 99: 4276–4282.CrossRefGoogle ScholarPubMed
Dispenzieri, A, Gertz, MA, Kyle, RA, et al. 2004. Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. J Clin Oncol 22: 3751–3757.CrossRefGoogle ScholarPubMed
Dispenzieri, A, Lacy, MQ, Zeldenrust, SR, et al. 2007. The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis. Blood 109: 465–470.CrossRefGoogle ScholarPubMed
Gertz, MA, Lacy, MQ, Dispenzieri, A, et al. 2007. Transplantation for amyloidosis. Curr Opin Oncol 19: 136–141.CrossRefGoogle ScholarPubMed
Goodman, HJB, Gillmore, JD, Lachman, HJ, et al. 2006. Outcome of autologous stem cell transplantation for AL amyloidosis in the UK. Br J Haematol 134: 417–425.CrossRefGoogle ScholarPubMed
Imamura, T, Ogata, M, Kohno, K, et al. 2006. Successful reduced intensity allogeneic stem cell transplantation for systemic AL amyloidosis. Am J Hematol 81: 281–283.CrossRefGoogle ScholarPubMed
Jaccard, A, Moreau, P, Leblond, V, et al. 2007. High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis. N Engl J Med 357: 1083–1093.CrossRefGoogle ScholarPubMed
Palladini, G & Merlini, G. 2011. Transplantation vs. conventional-dose therapy for amyloidosis. Curr Opin Oncol 23: 214–220.CrossRefGoogle ScholarPubMed
Sanchorawala, V, Wright, DG, Seldin, DC, et al. 2001. An overview of the use of high-dose melphalan with autologous stem cell transplantation for the treatment of AL amyloidosis. Bone Marrow Transplant 28: 637–642.CrossRefGoogle ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×